The US Department of Agriculture approved the genetically modified purple tomato to extend its shelf life and boost nutritional quality almost 15 years after its development.
According to biochemist Cathie Martin, she and her colleagues at Norfolk Plant Scientists (NPS) have been experimenting with pigment production in flowering plants for over two decades, and they've spent almost 15 months developing the purple tomato.
The NPS has been focusing on anthocyanins, the antioxidant-rich pigments that give blackberries and blueberries their signature shades.
Domesticated tomatoes already have genes to produce anthocyanins, but they are not 'turned on.' By carefully adding two genes, the tomatoes and juice become a rich source of antioxidants, because purple pigments are made in the whole tomato, not just the skins.
While there are already some purple-skinned tomatoes, their pigments mostly stop at the outer layers and don't accumulate in the fruit itself.
The NPS also emphasized that there is increasing evidence to show that antioxidants work much better when consumed within foods.
The USDA Animal and Plant Health Inspection Service (APHIS) reported that the tomato was modified to alter its color and enhance its nutritional quality, adding that the plant is unlikely to pose an increased plant pest risk compared to other cultivated tomatoes.
Nathan Pumplin, the CEO of NPS' US-based commercial business, said they are optimistic that they can begin limited distribution of purple tomatoes in the US by 2023.


Silver Prices Plunge in Asian Trade as Dollar Strength Triggers Fresh Precious Metals Sell-Off
RBI Holds Repo Rate at 5.25% as India’s Growth Outlook Strengthens After U.S. Trade Deal
Blue Origin’s New Glenn Achieves Breakthrough Success With First NASA Mission
NASA Resumes Cygnus XL Cargo Docking with Space Station After Software Fix
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Trump Signs Executive Order to Boost AI Research in Childhood Cancer
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
SpaceX Starship Test Flight Reaches New Heights but Ends in Setback
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
NASA Astronauts Wilmore and Williams Recover After Boeing Starliner Delay
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 



